SHC

Sotera Health is a high-quality, mission-critical sterilization and lab-services franchise (Sterigenics, Nordion, Nelson Labs) with durable, recurring demand from healthcare and pharma customers. The economics are excellent at the gross/operating level: FY2025 gross margin of 55.5% and operating margin of 25.6%, with revenue up 5.7% to $1.16B and broad-based growth — Sterigenics net revenue rose 8.3% to $755.8 million and Nordion 8.2% to $187.6 million, both driven by favorable pricing plus volume/mix. Net income jumped 75.6% to $77.9M and EPS to $0.27, and the business throws off strong cash, with $287.2 million of operating cash flow (up 28.1%) and $345M of cash on hand.

The offsetting concern is the capital structure and overhang risk. Liabilities/equity sits at a heavy 4.38x with $2.13B of long-term debt, retained earnings are still negative at -$532M, and the net margin is only 6.7% — the gap between the strong 25.6% operating margin and the thin net margin is interest expense on that leverage. Management's own risk-factor summary highlights its 'significant degree of leverage' and, most importantly, ongoing litigation 'related to the use, emissions and releases of EO' from its sterilization facilities, a tail risk that has historically been material (FY2022 swung to a -$234M net loss). Nelson Labs is also the soft spot, with revenue down 3.9% on a decline in expert advisory/consulting work.